Navigation Links
FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
Date:7/30/2009

SILVER SPRING, Md., July 30 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System (which includes the Optineb-ir device and accessories). TYVASO is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.

"We are thrilled to have a fourth approval from the FDA for treatment of this serious cardio-pulmonary condition," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I want to specially recognize Drs. Werner Seeger of Germany and Lew Rubin of the United States for their critical pioneering efforts in making this new therapy possible. TYVASO epitomizes the hopes and dreams we had in forming this company."

In connection with the TYVASO approval, United Therapeutics has agreed to Post-Marketing Commitments (PMC) to modify certain aspects of the TYVASO Inhalation System, perform a usability analysis and collect pharmacokinetic data to verify expected dosing with the modified device. "We are well underway with the modifications to the TYVASO Inhalation System," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer, "And we think these modifications will make the device more patient-friendly. In the meantime, patients will use the current version of the device." We have committed to complete the PMC no later than October 31, 2010.

Additionally, United Therapeutics has agreed to a Post-Marketing Requirement (PMR) to conduct a long-term observational study to evaluate the risk of oropharyngeal and pulmonary toxicities among patients using TYVASO. "We welcome the opportunity to gather further information on TYVASO's safety," continued Dr. Jeffs. We have committed to complete the PMR no later than December 15, 2013.

In the TRIUMPH-1 randomized, double-blind, 12-week placebo-controlled clinical trial, patients taking TYVASO in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance over those taking placebo (p<0.0005). The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects (>= 10%) seen with TYVASO in the placebo controlled clinical study were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain and diarrhea.

United Therapeutics plans to launch TYVASO in conjunction with its wholly-owned subsidiary, Lung Rx, Inc., in the United States at the beginning of September 2009.

Conference Call

United Therapeutics will host a half hour teleconference on July 31, 2009, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-852-6576, with international callers dialing 1-719-325-4788. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-888-203-1112, with international callers dialing 1-719-457-0820, and using conference code: 4416949.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

About TYVASO

TYVASO is an inhaled medicine used to treat PAH, a life-threatening disease that constricts the flow of blood through the pulmonary vasculature. TYVASO contains the same active ingredient (treprostinil) as REMODULIN (treprostinil sodium) Injection, which is also approved for the treatment of PAH. TYVASO is marketed by United Therapeutics and its wholly-owned subsidiary, Lung Rx, Inc.

Nearly all clinical experience has been on a background of an endothelin receptor antagonist or a phosphodiesterase type 5 inhibitor.

Important Safety Information for TYVASO

TYVASO is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance. TYVASO is intended for oral inhalation only. TYVASO is approved for use only with the TYVASO Inhalation System. The safety and efficacy of TYVASO have not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease). Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and any loss of drug effect. In patients with low systemic arterial pressure, TYVASO may cause symptomatic hypotension. TYVASO may also increase the risk of bleeding, particularly in patients receiving anticoagulants. The concomitant use of TYVASO with diuretics, antihypertensives or other vasodilators may increase the risk of systemic hypotension. Hepatic or renal insufficiency may increase exposure and decrease the tolerability of TYVASO. The most common side effects (>= 10%) seen with TYVASO in the placebo controlled clinical study were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain and diarrhea. Please see the TYVASO full prescribing information or patient information for further details.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Forward-looking Statements

Statements included in this press release concerning, among others, the benefits of TYVASO for patients, our future activities to improve the TYVASO Inhalation System and its usability, our conducting a post-marketing usability analysis of the modified TYVASO Inhalation System device, the timing of completing the usability analysis, our conducting a post-marketing observational study of TYVASO, the timing of completing the observational study, and our plans to commercialize TYVASO in the United States are "forward-looking statements" within the meaning of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K, which could cause actual results to differ materially from anticipated results. We are providing this information as of July 31, 2009, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

REMODULIN is a registered trademark of United Therapeutics Corporation.

TYVASO is a trademark of United Therapeutics Corporation.

Optineb( )is a registered trademark of NEBU-TEC GmbH.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward Hallowell, host ... social media that offer a rare glimpse into the mind of those people with ... York Times bestselling author, has described people with ADHD as having “Ferrari engines for ...
(Date:12/7/2016)... ... December 07, 2016 , ... The ... offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington ... needs treatment for a brain tumor. , Jason Bauer and his family are ...
(Date:12/7/2016)... ... , ... A. Kevin Spann Insurance, a New York-based firm offering insurance and ... a charity drive to raise funds that will benefit the Marine Corps League. , ... Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans ...
(Date:12/7/2016)... ... 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful ... Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 ... Delightful Deals on Botox® and Juvederm® just in time for the holiday ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is honored to be ... Best New Product Launch category. Gensuite’s entry on their EZ Scan feature detailed ... Events & Training Group is a professional event and training provider based in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... NORTH READING, Mass. , Dec. 7, 2016 ... Track and Trace Network for connecting the Life ... from the global marketplace, today announced that Tjoapack ... 50+ European pharmaceutical manufacturing customers comply with the ... Supply Chain Security Act (DSCSA) in 2017 and ...
(Date:12/7/2016)... According to a new market research report "Clinical Decision Support Systems Market ... Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), Application - Forecasts to 2021" ... Million by 2021 from USD 856.3 Million in 2016, at a CAGR ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
Breaking Medicine Technology: